Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia. (PEARL 3)

March 11, 2016 updated by: Sunovion

A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR short term among acutely psychotic patients with chronic schizophrenia.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

488

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • India
    • Andhra Pradesh
      • Vijayawada, Andhra Pradesh, India, 520002
        • Vijayawada Institute of Mental Health and Neurosciences
    • Andra Pradesh
      • Tirupati, Andra Pradesh, India, 517507
        • S.V. Medical College
    • Gujarat
      • Ahmedabad, Gujarat, India, 380006
        • Seth K M School of P G Medicine & Research
      • Vadodara, Gujarat, India, 391760
        • SBKS Medical Institute and Research Centre
    • Karnataka
      • Mangalore, Karnataka, India, 574160
        • Justice K.S. Hegde Charitable Hospital
      • Mysore, Karnataka, India, 570004
        • JSS Medical College and Hospital
    • Maharastra
      • Aurangabad, Maharastra, India, 431005
        • Shanti Nursing Home
      • Pune, Maharastra, India, 411004
        • Deenanath Mangeshkar Hospital and Research Centre
      • Sewagram, Maharastra, India, 442102
        • Mahatma Gandhi Institute of Medical Sciences
    • TamilNadu
      • Chennai, TamilNadu, India, 600003
        • Madras Medical College & Government General Hospital
  • Romania
      • Bucuresti, Romania
        • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
      • Oradea, Romania
        • Spitalul Clinic de Neurologie si Psihiatrie Oradea
    • Arad
      • Str. Octavian Goga nr. 17, Arad, Romania, 310022
        • Spitalul Clinic Județean De Urgența Arad
    • Bucuresti
      • Bdul Nicolae Grigorescu nr. 41, Bucuresti, Romania, 030440
        • Spitalul de Psihiatrie Titan "Dr. Constantin Gorgos"
      • Sos. Berceni nr. 10-12, Bucuresti, Romania, 041914
        • Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
    • Pitesti
      • Str. Negru Voda nr. 53, Pitesti, Romania, 110069
        • Spitalul Judetean Arges
  • Russian Federation
      • Arkhangelsk, Russian Federation, 163060
        • SEI of H.P. Educat. Northern SMU
      • Gatchina, Russian Federation, 188357
        • St. Petersburg SHI Psychiatrical Hosptial #1 n.a. Kaschenko
      • Moscow, Russian Federation, 107076
        • Moscow Scientific Research Institute of Psychiatry
      • Moscow, Russian Federation, 115522
        • Institution of RAMS Mental Health Research Center of RAMS
      • Nizhniy Novgorod, Russian Federation, 603 155
        • City Clinical Psichiatric Hospital #1
      • Samara, Russian Federation, 443016
        • SHI Samara Psychiatric Hospital
      • St. Petersburg, Russian Federation
        • City Psychiatric Hospital #2 of St. Nikolay Chudotvorets
      • St. Petersburg, Russian Federation
        • City Psychiatric Hospital #3 of Skvortsov-Stepanov
      • St. Petersburg, Russian Federation
        • City Psychiatric Hospital #4
      • St. Petersburg, Russian Federation
        • SHI City Psychoneurological Dispensary #7
      • St. Petersburg, Russian Federation
        • St. Petersburg GUZ City Psychiatric Hospital #6
  • Ukraine
      • Dnipropetrovsk, Ukraine, 49005
        • RCH n.a.I.I.Mechnikov, Reg.Cent. of Psychosom. Pathology
      • Donetsk, Ukraine, 83008
        • Chair of Psychiatry and Medical Psychology
      • Kyiv, Ukraine
        • Centre of Novel Treatment and Rehabilitation of Psychotic disorders
      • Kyviv, Ukraine
        • Kyiv City Psychoneurological Hospital
      • Lviv, Ukraine
        • Lviv Reg.St.Cl.Psych.Hosp
      • Odessa, Ukraine
        • Reg. Psychiatric Hospital
      • Poltava, Ukraine
        • Poltava Regional Clinical Psychiatric Hospital,
      • Simferopol, Ukraine
        • Crimean republican Clinical Psychiatric Hospital
    • Stepanovka
      • Kherson,vil., Stepanovka, Ukraine, 73488
        • Kherson Regional Psychiatric Hospital
  • United States
    • Arkansas
      • Little Rock, Arkansas, United States, 72211
        • Woodland International Research Group
      • Little Rock, Arkansas, United States, 72201
        • K&S Professional Research Services, LLC
    • California
      • Cerritos, California, United States, 90703
        • Clinical Pharmacological Studies, Inc.
      • Cerritos, California, United States, 90703
        • Comprehensive Neuroscience, Inc
      • Costa Mesa, California, United States, 92647
        • Clinical Innovations, Inc.
      • Escondido, California, United States, 92025
        • Synergy Escondido
      • Garden Grove, California, United States, 92645
        • Collaborative Neuroscience Network
      • Long Beach, California, United States, 90813
        • Apostle Clinical Trials, Inc.
      • Paramount, California, United States, 90723
        • California Clinical Trials
      • Pasadena, California, United States, 91107
        • Pasadena Research Institute
      • Pico Rivera, California, United States, 90660
        • CNRI-Los Angeles. LLC
      • Riverside, California, United States, 92647
        • Clinical Innovations, Inc.
      • San Diego, California, United States, 92126
        • Cnri-San Diego
      • Sandeigo, California, United States, 92103
        • UCSD Medical Center
    • Colorado
      • Highlands Ranch, Colorado, United States, 80103
        • Segal Institute for Clinical Research
    • District of Columbia
      • Washington, District of Columbia, United States, 20016
        • Comprehensive NeuroScience, Inc.
    • Florida
      • Bradenton, Florida, United States, 34208
        • Florida Clinical Research Center
      • Fruitland Park, Florida, United States, 34731
        • Florida Clinical Research Center, LLC
    • Louisiana
      • Lake Charles, Louisiana, United States, 70601
        • Lake Charles Clinical Trials
      • Shreveport, Louisiana, United States, 71104
        • Booker, J. Gary, MD. APMC
    • Mississippi
      • Flowood, Mississippi, United States, 39232
        • Precise Clinical Research
    • Missouri
      • St Charles, Missouri, United States, 63301
        • St. Charles Psychiatric Associates
      • St. Louis, Missouri, United States, 63118
        • St. Louis Research, Inc.
    • New Jersey
      • Willingboro, New Jersey, United States, 08046
        • CRI Worldwide
    • New York
      • Holliswood, New York, United States, 11423
        • Comprehensive Neuroscience, Inc
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27104
        • Segal Institute for Clinical Research
    • Texas
      • Austin, Texas, United States, 78756
        • Future Search Trials of Neurology
      • Austin, Texas, United States, 78729
        • Community Clinical Research
      • Dallas, Texas, United States, 75243
        • Pillar Clinical Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 71 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Provide written informed consent and aged between 18 and 75 years of age.
  • Meets DSM-IV™ criteria for a primary diagnosis of schizophrenia.
  • Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.
  • Able and agrees to remain off prior antipsychotic medication for the duration of study.
  • Good physical health on the basis of medical history, physical examination, and laboratory screening.
  • Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.

Exclusion Criteria:

  • Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
  • Any chronic organic disease of the CNS (other than schizophrenia).
  • Used investigational compound within 30 days.
  • Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Drug: Placebo
Matching Placebo to Lurasidone or Quetiapine
Active Comparator: Quetiapine XR
Drug: Quetiapine XR
Quetiapine XR 600mg
Experimental: Lurasidone 80mg
Drug: Lurasidone
Lurasidone 80 mg tablets
Drug: Lurasidone
Lurasidone 4 40 mg tablets
Experimental: Lurasidone 160mg
Drug: Lurasidone
Lurasidone 80 mg tablets
Drug: Lurasidone
Lurasidone 4 40 mg tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase
Time Frame: Week 6
The PANSS (Positive and Negative Syndrome Scale) is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.
Week 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary Outcome: CGI-S From Baseline to the End of the Double-blind Treatment
Time Frame: 6-Weeks
Clinical Global Impression of Severity is a clinician-rated assessment of the subject's current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 ('normal', not ill) to 7 (extremely ill).
6-Weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sunovion

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2008

Primary Completion (Actual)

July 1, 2010

Study Completion (Actual)

July 1, 2010

Study Registration Dates

First Submitted

November 10, 2008

First Submitted That Met QC Criteria

November 12, 2008

First Posted (Estimate)

November 13, 2008

Study Record Updates

Last Update Posted (Estimate)

March 17, 2016

Last Update Submitted That Met QC Criteria

March 11, 2016

Last Verified

March 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • D1050233

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on Lurasidone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe